ahlam1399
06-28-2016, 04:13 PM
BRIEF-Bioline says filed regulatory submissions to start Phase 2A trial for BL-8040
* Filed regulatory submissions required to commence phase 2atrial for bl-8040 in combination with keytruda in patients withpancreatic cancerhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0746DqMA3gA:VkwfJ66vDv8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0746DqMA3gA:VkwfJ66vDv8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/0746DqMA3gA
* Filed regulatory submissions required to commence phase 2atrial for bl-8040 in combination with keytruda in patients withpancreatic cancerhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0746DqMA3gA:VkwfJ66vDv8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=0746DqMA3gA:VkwfJ66vDv8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=0746DqMA3gA:VkwfJ66vDv8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/0746DqMA3gA